Impact of recombinant DNA technology in pharmacology.
Bruno
F
F
Maggi
A
A
D000900:Anti-Bacterial Agents / Q000096:biosynthesis; D001419:Bacteria / Q000235:genetics; D004274:DNA, Recombinant; D030342:Genetic Diseases, Inborn / Q000175:diagnosis / Q000628:therapy; D005818:Genetic Engineering; D006801:Humans; D007328:Insulin / Q000138:chemical synthesis; D007372:Interferons / Q000138:chemical synthesis; D013678:Technology, Pharmaceutical; D014612:Vaccines / Q000138:chemical synthesis; D014765:Viral Vaccines / Q000138:chemical synthesis
D000900:Anti-Bacterial Agents; D004274:DNA, Recombinant; D007328:Insulin; D014612:Vaccines; D014765:Viral Vaccines; D007372:Interferons